Ambar Bhattacharyya

Background

Ambar Bhattacharyya is a Managing Director at Maverick Ventures, the venture capital arm of Maverick Capital, based in San Francisco ¹. He has spent nearly 20 years investing in early-stage healthcare and technology companies ¹. Prior to joining Maverick in 2015, Bhattacharyya was an investor at Bessemer Venture Partners (2010-2015) and Bain Capital Ventures (2006-2008) ². He began his career at Bain & Company as a Senior Associate Consultant (2003-2006) and also worked at The Bridgespan Group (2004-2005) ².

Before his venture career, Bhattacharyya served as assistant to the CEO at MinuteClinic, where he helped the company grow its national footprint prior to its acquisition by CVS ³. This operational experience in healthcare shaped his investing thesis; he has noted that at MinuteClinic he observed that “people were willing to pay all cash, out of pocket, for what they deemed to be a ‘better’ health-care experience” ³.

Bhattacharyya holds an M.B.A. from Harvard Business School and a B.S. and B.A. from the University of Pennsylvania, where he studied economics and psychology ^{3 1}. He is an advisor to the California Healthcare Foundation Innovation Fund and an Aspen Institute Health Innovators Fellow ¹.

He was named to Fortune’s “40 Under 40” list in the healthcare category in 2020 ³, Business Insider’s “30 leaders under 40 transforming healthcare,” recognized as a Global Shaper by the World Economic Forum ⁴, and included on Forbes’ Midas Brink List of the world’s best venture capital investors in 2025 ¹.

During his venture career, Bhattacharyya has led or been actively involved in investments resulting in 16 IPOs and acquisitions, with six companies achieving valuations of over $1B in the public markets ¹. He currently serves on the board of directors at Centivo, Cityblock Health, and Hims & Hers Health, and has held board seats at Artemis Health, BlueFlag Security, and Daymark Health ^{5 6}.

Stated Thesis

Bhattacharyya and Maverick Ventures publicly describe their focus as investing at the intersection of healthcare and technology, with a particular emphasis on consumer-facing health applications and the transformative potential of AI ⁷.

Bhattacharyya has stated that a core part of his thesis centers on the shift from “sick care” to preventive healthcare: “The root cause of the interest in these areas is the desire to do more preventive health care, turning the system from a ‘sick care’ system to a ‘health system’” ³. He has emphasized the fundamental misalignment in traditional fee-for-service models, where “the financial incentives are aligned with treating people after they are sick, not necessarily spending time with a patient beforehand” ³.

On consumer healthcare, he has identified a key thesis around healthcare segmentation: “There remains a major lack of segmentation in health care, and there are millions of patients who are willing to pay for their version of ‘better’” ³.

On AI in healthcare, Bhattacharyya has stated: “Artificial intelligence and machine learning in health care are not hypotheticals anymore” ³. He emphasizes a thematic approach to investing that identifies large megatrends growing exponentially, including AI and GLP-1 therapies ⁴. Maverick focuses on five key healthcare stakeholders — providers, payers, employers, pharma companies, and consumers — across approximately $4 trillion in annual healthcare spend ⁴.

Maverick Ventures publicly states that it backs “a few teams per year so they can be true partners to each company” and provides a “no walls” approach between Maverick Capital’s public and private investment teams ⁷.

Inferred Thesis

Based on 24 verified investments attributed to Bhattacharyya or made during his tenure at Maverick Ventures (2015-present), the following patterns emerge. Note: this represents a subset of Maverick Ventures’ 124+ total investments ⁸; some investments are attributed to the firm broadly rather than to Bhattacharyya individually.

Sector distribution (based on 24 verified investments): Healthcare and healthtech dominate the portfolio — 18 of 24 investments (75%) are in healthcare or healthtech. Of the healthcare investments: 7 are in healthcare delivery/services (Cityblock, Centivo, Devoted Health, Oula, Daymark Health, Aligned Marketplace, Nourish), 4 are in health technology platforms (Hims & Hers, Garner Health, Notable Health, Claim Health), 3 are in life sciences/biotech (Caribou Biosciences, House Rx, Mandolin), 2 are in healthcare data/AI (ConcertAI, Collective Medical Technologies), and 2 are in consumer health (Chapter, Vetcove). The remaining 6 of 24 (25%) span enterprise software (Retool), AI/ML infrastructure (MosaicML), cybersecurity (BioCatch), quantum technology (Infleqtion), consumer tech (Coupang, LTK).

Stage distribution (based on 24 verified investments): 9 of 24 (38%) at seed stage (Hims & Hers, Cityblock, Chapter, Vetcove, House Rx, Notable Health, Daymark Health, Claim Health, Infleqtion); 9 of 24 (38%) at Series A (Centivo, Devoted Health, Garner Health, Collective Medical Technologies, Nourish, Oula, Mandolin, BioCatch, MosaicML); 6 of 24 (25%) at Series B or later (Caribou Biosciences, ConcertAI, Retool, Coupang, LTK, Aligned Marketplace follow-on). The roughly even split between seed and Series A is consistent with Maverick’s stated focus on seed through Series B.

Geographic concentration: The majority of verified portfolio companies are headquartered in the United States, with notable concentration in New York City (Cityblock, Centivo, Garner Health, Chapter, Devoted Health) and San Francisco/Bay Area (Hims & Hers, Notable Health, MosaicML, Retool). The one notable international outlier is Coupang (South Korea).

Co-investor patterns: Frequent co-investors across Bhattacharyya’s deals include Thrive Capital (Hims & Hers, Cityblock, Garner Health), Bain Capital Ventures (Centivo), F-Prime Capital (Centivo, Notable Health), 8VC (Oula, Notable Health), and Greylock Partners (Notable Health, Mandolin). There is a pattern of backing companies where other healthcare-focused funds also invest.

Founder profile patterns: Bhattacharyya shows a strong preference for founders with deep operational experience in healthcare. Cityblock’s Iyah Romm came from Sidewalk Labs/Google; Devoted Health’s founders include former CMS officials; House Rx’s founders came from Flatiron Health; and Hims & Hers founder Andrew Dudum had consumer product experience. Several portfolio companies have founders with clinical backgrounds (Daymark Health’s Dr. Justin Bekelman, Nourish’s team of registered dietitians).

Notable gap between stated and inferred thesis: While Maverick publicly emphasizes consumer health, the portfolio leans more heavily toward B2B healthcare infrastructure (employer health plans, provider tools, care delivery platforms) than pure consumer applications. The consumer-facing investments (Hims & Hers, Chapter) are present but represent a minority of the overall portfolio.

Portfolio

Note: This table represents approximately 24 verified investments out of Maverick Ventures’ 124+ total portfolio companies ⁸. Investments marked with “~” use approximate dates based on available data. Some investments listed on the Maverick Ventures portfolio page could not be attributed specifically to Bhattacharyya versus other Maverick team members.

Key exits: Hims & Hers IPO (2021, $HIMS) ⁹; Caribou Biosciences IPO (2021, $CRBU) ¹⁵; MosaicML acquired by Databricks for $1.3B (2023) ¹⁹; BioCatch acquired by Permira at $1.3B valuation (2024) ¹⁶; One Medical IPO and subsequent Amazon acquisition ⁷; Coupang IPO ($CPNG) ⁷.

In Their Own Words

“It is a rare opportunity to back a team that not only has real-world experience managing clinical services for high-need, high-cost populations, but also has shipped consumer technology at Google scale.” — Ambar Bhattacharyya, on investing in Cityblock Health, VCNewsDaily, January 2018 ¹⁰.

“Quite simply, Hims & Hers is redefining what consumer healthcare is. This is a telehealth company that is turning the healthcare system on its head, and putting the power into the hands of the consumer when it comes to defining their own healthcare experience.” — Ambar Bhattacharyya, on joining the Hims & Hers board of directors, Nasdaq press release, March 2021 ⁶.

“This additional investment underscores our commitment to Aligned Marketplace’s industry-leading nationwide advanced primary care marketplace. We believe that advanced primary care will play a vital role in shaping the future of a healthy workforce.” — Ambar Bhattacharyya, on Aligned Marketplace’s seed extension, PR Newswire, January 2025 ²⁷.

“Daymark Health represents the next evolution in specialty value-based care companies — optimizing care for the special and complex population of patients with cancer.” — Ambar Bhattacharyya, on co-leading Daymark Health’s seed round, PR Newswire, April 2025 ²⁶.

“The single most important decision you will make is the who — it’s the people. Truly on every layer of the company, from who you take capital from, from who is on your board, from who your co-founders are, to who you hire.” — Ambar Bhattacharyya, The Full Ratchet podcast, Investor Stories 379 ³¹.

“The advice that I give to folks when they start here at Maverick is to really find your own voice… Be as authentic as you can, and that’ll pay the most dividends in the long run.” — Ambar Bhattacharyya, The Full Ratchet podcast, Investor Stories 379 ³¹.

“One of the biggest shifts in how I thought about investing since I started is… I was always looking for what is the really clear bright line product differentiation. The power of network effects — until I was able to see it in my career, I don’t think I really understood how powerful they could be.” — Ambar Bhattacharyya, The Full Ratchet podcast, Investor Stories 376 ³².

“My background, I grew up mostly in rural America. My father’s a physician, immigrant physician from Calcutta.” — Ambar Bhattacharyya, The Full Ratchet podcast, Episode 438 ⁴.

What Founders Say

Andrew Dudum, CEO and Co-Founder of Hims & Hers Health, stated upon Bhattacharyya’s appointment to the board: “As we continue our work of reimagining the modern healthcare experience, I am thrilled to have… Ambar Bhattacharyya joining us on this mission.” — Andrew Dudum, Hims & Hers press release, March 2021 ⁶.

Iyah Romm, Co-Founder and former CEO of Cityblock Health, appeared jointly with Bhattacharyya on TechCrunch’s Extra Crunch Live in 2021, discussing their investor-founder relationship from Cityblock’s Series A through later rounds ³³. No independently sourced founder testimonials with specific quotes about Bhattacharyya’s effectiveness as a board member or investor were found beyond the Hims & Hers board appointment statement.

No independently sourced founder testimonials found beyond the above. Portfolio founder quotes praising Bhattacharyya’s specific contributions as a board member or investor advisor were not located through dedicated search.

Sources